FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compounds of formula V or Va and their pharmaceutically acceptable salts. In formula V or Va D is selected from the group, including linear hydrocarbon groups, which contain carbon chain, containing from 1 to 2 carbon atoms; R4 stands for -CN; R2 and R5 stand for H; each of R3 and R6 is independently selected from the group, including -H, halogen, -NR12R13 and -(CH2)0-1R14; R12 and R13 together with atoms, which they are bound to, can form monocyclic ring, containing from 5 to 8 ring elements; R14 stands for each of R17-R21 is independently selected from the group, including -H, halogen, -O-(C1-C6)halogenalkyl, -CN, -OH, -OBn, -OSO2NR15R16, -O-(C1-C6)alkyl; R15 and R16 are selected from H; each of R7-R11 is independently selected from the group, including -H, halogen, -OH, -OBn, -OSO2NR15R16; R15 and R16 are independently selected from the group, including H Invention also relates to pharmaceutical composition.
EFFECT: invention compounds possess inhibiting activity with respect to STS and/or aromatase.
25 cl, 2 dwg
Title | Year | Author | Number |
---|---|---|---|
IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2678305C1 |
(AZA)INDOLE-, BENZOTHIOPHENE- AND BENZOFURAN-3-SULPHONAMIDES | 2017 |
|
RU2767904C2 |
PYRAZOLOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | 2015 |
|
RU2733400C2 |
HISTONES DEACETYLASES (HDACS) INHIBITORS | 2013 |
|
RU2629947C2 |
PROTEIN TYROSINE KINASE ACTIVITY INHIBITORS | 2009 |
|
RU2533827C2 |
CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679609C1 |
PRODRUG FORMING COMPOUNDS | 2014 |
|
RU2667942C2 |
TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2697090C1 |
Authors
Dates
2016-01-10—Published
2010-08-23—Filed